|
Q3 2024
|
6 |
63,573 |
CRSP, CTNM, RPTX, SKYE
|
13F-HR
|
11/8/2024 |
000095012324010733 |
|
Q2 2024
|
8 |
77,296 |
CRSP, Contineum Therapeutics, Inc., Skye Bioscience, Inc., RPTX
|
13F-HR
|
8/7/2024 |
000095012324007328 |
|
Q1 2024
|
7 |
103,136 |
CRSP, Skye Bioscience, Inc., RPTX, GRTS
|
13F-HR
|
5/3/2024 |
000095012324003797 |
|
Q4 2023
|
7 |
388,843 |
RYZB, CRSP, RPTX, GRTS
|
13F-HR
|
2/8/2024 |
000095012324001156 |
|
Q3 2023
|
8 |
188,112 |
RYZB, RPTX, CRSP, ADVM
|
13F-HR
|
11/3/2023 |
000095012323009395 |
|
Q2 2023
|
8 |
84,298 |
RPTX, CRSP, ADVM, GRTS
|
13F-HR
|
8/9/2023 |
000095012323007098 |
|
Q1 2023
|
7 |
47,972 |
CRSP, GRTS, PASG, CBAY
|
13F-HR
|
5/10/2023 |
000095012323004367 |
|
Q4 2022
|
7 |
48,328 |
CRSP, GRTS, PASG, CBAY
|
13F-HR
|
2/9/2023 |
000095012323001275 |
|
Q3 2022
|
8 |
58,655 |
CRSP, GRTS, PASG, ADVM
|
13F-HR
|
11/10/2022 |
000095012322011472 |
|
Q2 2022
|
8 |
65,230 |
CRSP, PASG, GRTS, ADVM
|
13F-HR
|
8/11/2022 |
000095012322008452 |
|
Q1 2022
|
10 |
100,171 |
CRSP, PASG, GRTS, CRNX
|
13F-HR
|
5/10/2022 |
000095012322005030 |
|
Q4 2021
|
10 |
186,975 |
GRTS, CRSP, PASG, ALGS
|
13F-HR
|
2/11/2022 |
000095012322001851 |
|
Q3 2021
|
11 |
241,512 |
CRSP, PASG, GRTS, ALGS
|
13F-HR
|
11/12/2021 |
000095012321014984 |
|
Q2 2021
|
11 |
301,807 |
CRSP, PASG, ALGS, GRTS
|
13F-HR
|
8/12/2021 |
000095012321010561 |
|
Q1 2021
|
11 |
513,262 |
CRSP, PASG, ALGS, ADVM
|
13F-HR
|
5/6/2021 |
000095012321005457 |
|
Q4 2020
|
12 |
962,968 |
CRSP, NARI, ALGS, ADVM
|
13F-HR
|
2/16/2021 |
000095012321002373 |
|
Q3 2020
|
11 |
546,369 |
CRSP, ADVM, APRE, FLXN
|
13F-HR
|
11/12/2020 |
000095012320011532 |
|
Q2 2020
|
12 |
696,065 |
CRSP, ADVM, APRE, AKRO
|
13F-HR
|
7/20/2020 |
000110465920084768 |
|
Q1 2020
|
9 |
364,636 |
CRSP, ADVM, AKRO, VCYT
|
13F-HR
|
4/28/2020 |
000110465920052226 |
|
Q4 2019
|
7 |
331,845 |
CRSP, VCYT, GRTS, OCUL
|
13F-HR
|
1/21/2020 |
000110465920005491 |
|
Q3 2019
|
8 |
258,454 |
CRSP, VCYT, GRTS, BOLD
|
13F-HR
|
10/8/2019 |
000110465919053357 |
|
Q2 2019
|
9 |
343,186 |
CRSP, VCYT, GRTS, BOLD
|
13F-HR
|
7/12/2019 |
000110465919039996 |
|
Q1 2019
|
9 |
303,568 |
CRSP, VCYT, BOLD, CBAY
|
13F-HR
|
4/5/2019 |
000110465919020144 |
|
Q4 2018
|
10 |
202,020 |
CRSP, VCYT, BOLD, OCUL
|
13F-HR
|
1/22/2019 |
000110465919002754 |
|
Q3 2018
|
10 |
294,005 |
CRSP, BOLD, VCYT, OCUL
|
13F-HR
|
10/5/2018 |
000110465918060749 |
|
Q2 2018
|
9 |
320,525 |
CRSP, BOLD, OCUL, CBAY
|
13F-HR
|
7/13/2018 |
000110465918045045 |
|
Q1 2018
|
8 |
312,675 |
CRSP, BOLD, AKAOQ, OCUL
|
13F-HR
|
5/3/2018 |
000110465918030300 |
|
Q4 2017
|
7 |
95,029 |
BOLD, AKAOQ, OCUL, CBAY
|
13F-HR
|
1/25/2018 |
000110465918003973 |
|
Q3 2017
|
8 |
131,378 |
BOLD, IMDZ, AKAOQ, OCUL
|
13F-HR
|
10/13/2017 |
000110465917062084 |
|
Q2 2017
|
8 |
127,127 |
BOLD, AKAOQ, IMDZ, OCUL
|
13F-HR
|
8/2/2017 |
000110465917048730 |
|
Q1 2017
|
8 |
137,509 |
AKAOQ, BOLD, CLVSQ, OCUL
|
13F-HR
|
4/7/2017 |
000110465917022191 |
|
Q4 2016
|
7 |
102,740 |
BOLD, OCUL, CLVSQ, AKAOQ
|
13F-HR
|
1/18/2017 |
000110465917002761 |
|
Q3 2016
|
7 |
89,691 |
BOLD, IMDZ, OCUL, CLVSQ
|
13F-HR
|
10/24/2016 |
000110465916151423 |
|
Q2 2016
|
5 |
98,672 |
GKOS, OCUL, CLVSQ, AKAOQ
|
13F-HR
|
7/28/2016 |
000110465916135018 |
|
Q1 2016
|
7 |
138,515 |
GKOS, FPRX, OCUL, CLVSQ
|
13F-HR
|
4/25/2016 |
000110465916113751 |
|
Q4 2015
|
7 |
170,904 |
GKOS, FPRX, OCUL, CLVSQ
|
RESTATEMENT
|
5/5/2016 |
000110465916118185 |
|
Q3 2015
|
7 |
174,363 |
GKOS, CLVSQ, OCUL, FPRX
|
13F-HR
|
10/28/2015 |
000110465915073439 |
|
Q2 2015
|
5 |
78,844 |
CLVSQ, FPRX, AKAOQ, Biotie Therapies Corp.
|
13F-HR
|
7/15/2015 |
000110465915051249 |
|
Q1 2015
|
6 |
113,697 |
CLVSQ, FPRX, AKAOQ, CBAY
|
13F-HR
|
4/23/2015 |
000110465915029755 |
|
Q4 2014
|
5 |
104,586 |
CLVSQ, FPRX, AKAOQ, CBAY
|
RESTATEMENT
|
4/23/2015 |
000110465915029709 |